Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Pyxis Oncology (PYXS) EBITDA (2024 - 2025)

Pyxis Oncology (PYXS) has disclosed EBITDA for 2 consecutive years, with -$21.9 million as the latest value for Q3 2025.

  • On a quarterly basis, EBITDA fell 5.68% to -$21.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$97.4 million, a N/A change, with the full-year FY2024 number at -$77.2 million, down 4.74% from a year prior.
  • EBITDA was -$21.9 million for Q3 2025 at Pyxis Oncology, down from -$18.4 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$3.4 million in Q1 2024 to a low of -$35.8 million in Q4 2024.